Biopharmas raising money in public or private financings, including: Actitrexx, Adamas, Argobio, Aslan, Avita, Biocorrx, Cardiol, Celcuity, Karuna, Lixte, Mannkind, Mesoblast, Morphic, Navidea, Redhill, Rejuvenate, Scisparc, Xortx.

Biopharmas raising money in public or private financings, including: Briacell, Carisma, Dtx, EG 427, Fog Pharmaceuticals, Karuna, Lixte, Mannkind, Medilink, Nabriva, Saliogen, Satsuma, Sernova.

Biopharmas raising money in public or private financings, including: Artiva, Edesa, Ibere, Liscure.

Eight months after Beijing-based Yisheng Biopharma Co. Ltd. unveiled its recombinant protein vaccine candidate for COVID-19, YS-SC2-010, the company raised $130 million in a series B round to pave way for the vaccine to enter clinical trials in the second quarter of this year, the company’s CEO David Shao told BioWorld.

Cancer immunotherapy developer Xilio Therapeutics Inc. has raised $95 million in series C financing to support its efforts to move a duo of tumor-selective candidates into the clinic. IND applications for both its interleukin-2 agonist, XTX-202, and anti-cytotoxic T-lymphocyte-associated protein 4 antibody, XTX-101, are planned for this year.

Biopharmas raising money in public or private financings, including: 180 Life Sciences, Adamas, Antibe, Aslan, Avita, Cellarity, Cullgen, Halozyme, Inflarx, Predictive Oncology, Vividion.

Biopharmas raising money in public or private financings, including: Aikido, Basilea, Briacell, Celcuity, Cleveland, Halozyme.